Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in combination with immune checkpoint inhibitors for sarcoma treatment

Chinese Anti-Cancer Association(CACA)Musculoskeletal Tumor and Metastatic Bone Tumor Society

doi:10.3969/j.issn.2095-252X.2023.05.010

Home>Articles>Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in combination with immune checkpoint inhibitors for sarcoma treatment

DOI: 10.3969/j.issn.2095-252X.2023.05.010

Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in combination with immune checkpoint inhibitors for sarcoma treatment

Chinese Anti-Cancer Association(CACA)Musculoskeletal Tumor and Metastatic Bone Tumor Society

Machine-generated Keywords：

Publication Date：2023-05-19

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：7( 374-380 )

Chinese Journal of Bone and Joint

ISTIC

ISSN：2095-252X

Year, Vol.(Issue)：2023,12(5)